Calliditas Therapeutics announces full results from the NefIgArd Phase 3 trial published in The Lancet

/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced publication in The Lancet of the full data...

Related Keywords

Leicester ,United Kingdom ,Stockholm ,Sweden ,United States ,American ,Jonathanm Barratt , ,European Commission ,Exchange Commission ,United States Federal Drug Administration ,University Of Leicester ,European Union Member States ,Nasdaq Stockholm ,Igard Study ,Primary Iga ,Mayer Professor ,Renal Medicine ,Chief Executive Officer ,Investor Relations ,Full Prescribing ,Iga Nephropathy ,Primary Immunoglobulin ,American Depositary Shares ,Nasdaq Global Select Market ,Private Securities Litigation Reform Act ,Calliditas Therapeutics ,